Home
Live Updates
Enzalutamide Receives Go Ahead From European Commission in nmHSPC : comparemela.com
Enzalutamide Receives Go Ahead From European Commission in nmHSPC
The European Commission has approved enzalutamide as monotherapy and in combination with ADT in BCR nonmetastatic hormone-sensitive prostate cancer.
Related Keywords
Barcelona ,
Comunidad Autonoma De Cataluna ,
Spain ,
Antonio Alcaraz ,
Ahsan Arozullah ,
Oncology Development At Astellas ,
University Hospital Clinic Of Barcelona ,
Department Of Urology ,
European Commission ,
University Hospital Clinic ,
Medicinal Products ,
Human Use ,
European Medicines Agency ,
Oncology Development ,
Enzalutamide ,
Bcr Nonmetastatic Hormone Sensitive Prostate Cancer ,
Phd ,
comparemela.com © 2020. All Rights Reserved.